bcl-2-specific siRNAs restore Gemcitabine sensitivity in human pancreatic cancer cells

Journal of Cellular and Molecular Medicine

Volumn 11, Issue 2, 2007, Pages 349-361

  Okamoto, Kinya ^a,b   Ocker, Matthias ^a,d   Neureiter, Daniel ^c   Dietze, Otto ^c   Zopf, Steffen ^a   Hahn, Eckhart G ^a   Herold, Christoph ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b TOTTORI UNIVERSITY   (Japan)

^c PARACELSUS MEDICAL UNIVERSITY   (Austria)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Bcl 2; Gemcitabine; Pancreatic cancer; RNAi; SiRNA

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE; SMALL INTERFERING RNA;

ADENOCARCINOMA; ARTICLE; DOSE RESPONSE; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; PANCREAS TUMOR; PATHOLOGY; PROTO ONCOGENE; TIME; TUMOR CELL LINE;

ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENES, BCL-2; HUMANS; PANCREATIC NEOPLASMS; RNA, SMALL INTERFERING; TIME FACTORS; TRANSFECTION;

MUS MUSCULUS;

EID: 34247881817     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2007.00013.x     Document Type: Article

References (38)

1. Keighley MR. Gastrointestinal cancers in Europe. Aliment Pharmacol Ther. 2003 18 : 7 30.
2. DiMagno EP, Reber HA, Tempero MA. AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. Gastroenterology. 1999 117 : 1464 84.
3. Simon B, Printz H. Epidemiological trends in pancreatic neoplasias. Dig Dis. 2001 19 : 6 14.
4. Raraty MG, Magee CJ, Ghaneh P, Neoptolemos JP. New techniques and agents in the adjuvant therapy of pancreatic cancer. Acta Oncol. 2002 41 : 582 95.
5. Nitecki SS, Sarr MG, Colby TV, van Heerden JA. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg. 1995 221 : 59 66.
6. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004 363 : 1049 57.
7. Schniewind B, Christgen M, Kurdow R, Haye S, Kremer B, Kalthoff H, Ungefroren H. Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis. Int J Cancer. 2004 109 : 182 8.
8. Bold RJ, Chandra J, McConkey DJ. Gemcitabineinduced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 content. Ann Surg Oncol. 1999 6 : 279 85.
9. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001 411 : 494 8.
10. Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 2001 15 : 188 200.
11. Zamore PD, Tuschl T, Sharp PA, Bartel DP. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell. 2000 101 : 25 33.
12. Hannon GJ. RNA interference. Nature. 2002 418 : 244 51.
13. Martinez J, Patkaniowska A, Urlaub H, Luhrmann R, Tuschl T. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell. 2002 110 : 563 74.
14. Wacheck V, Heere-Ress E, Halaschek-Wiener J, Lucas T, Meyer H, Eichler HG, Jansen B. Bcl-2 antisense oligonucleotides chemosensitize human gastric cancer in a SCID mouse xenotransplantation model. J Mol Med. 2001 79 : 587 93.
15. Jansen B, Wacheck V, Heere-Ress E, Schlagbauer- Wadl H, Hoeller C, Lucas T, Hoermann M, Hollenstein U, Wolff K, Pehamberger H. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet. 2000 356 : 1728 33.
16. Xu Z, Friess H, Solioz M, Aebi S, Korc M, Kleeff J, Buchler MW. Bcl-x(L) antisense oligonucleotides induce apoptosis and increase sensitivity of pancreatic cancer cells to gemcitabine. Int J Cancer. 2001 94 : 268 74.
17. Campani D, Esposito I, Boggi U, Cecchetti D, Menicagli M, De Negri F, Colizzi L, Del Chiaro M, Mosca F, Fornaciari G, Bevilacqua G. Bcl-2 expression in pancreas development and pancreatic cancer progression. J Pathol. 2001 194 : 444 50.
18. Miyamoto Y, Hosotani R, Wada M, Lee JU, Koshiba T, Fujimoto K, Tsuji S, Nakajima S, Doi R, Kato M, Shimada Y, Imamura M. Immunohistochemical analysis of Bcl-2, Bax, Bcl-X, and Mcl-1 expression in pancreatic cancers. Oncology. 1999 56 : 73 82.
19. Ocker M, Neureiter D, Lueders M, Zopf S, Ganslmayer M, Hahn EG, Herold C, Schuppan D. Variants of bcl-2 specific siRNA for silencing antiapoptotic bcl-2 in pancreatic cancer. Gut. 2005 54 : 1298 308.
20. Neureiter D, Zopf S, Dimmler A, Stintzing S, Hahn EG, Kirchner T, Herold C, Ocker M. Different capabilities of morphological pattern formation and its association with the expression of differentiation markers in a xenograft model of human pancreatic cancer lines. Pancreatology. 2005 5 : 387 97.
21. Ocker M, Herold C, Ganslmayer M, Hahn EG, Schuppan D. The synthetic retinoid adapalene inhibits proliferation and induces apoptosis in colorectal cancer cells in vitro. Int J Cancer. 2003 107 : 453 9.
22. Sun J, Blaskovich MA, Knowles D, Qian Y, Ohkanda J, Bailey RD, Hamilton AD, Sebti SM. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine. Cancer Res. 1999 59 : 4919 26.
23. Sasaki M, Kumazaki T, Takano H, Nishiyama M, Mitsui Y. Senescent cells are resistant to death despite low Bcl-2 level. Mech Ageing Dev. 2001 122 : 1695 706.
24. Burris HA, III., Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hott DD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997 15 : 2403 13.
25. Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabitti P, Uomo G, Cigolari S, Testa A, Maiello E, Lopez M. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer. 2002 94 : 902 10.
26. Rocha Lima CM, Savarese D, Bruckner H, Dudek A, Eckardt J, Hainsworth J, Yunus F, Lester E, Miller W, Saville W, Elfring GL, Locker PK, Compton LD, Miller LL, Green MR. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol. 2002 20 : 1182 91.
27. Bergman AM, Pinedo HM, Talianidis I, Veerman G, Loves WJ, van der Wilt CL, Peters GJ. Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. Br J Cancer. 2003 88 : 1963 70.
28. Hopkins-Donaldson S, Cathomas R, Simoes-Wust AP, Kurtz S, Belyanskaya L, Stahel RA, Zangemeister-Wittke U. Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment. Int J Cancer. 2003 106 : 160 6.
29. Lebedeva I, Stein CA. Antisense oligonucleotides: promise and reality. Annu Rev Pharmacol Toxicol. 2001 41 : 403 19.
30. Stahel RA, Zangemeister-Wittke U. Antisense oligonucleotides for cancer therapy-an overview. Lung Cancer. 2003 41 : S81 8.
31. Chleq-Deschamps CM, LeBrun DP, Huie P, Besnier DP, Warnke RA, Sibley RK, Cleary ML. Topographical dissociation of BCL-2 messenger RNA and protein expression in human lymphoid tissues. Blood. 1993 81 : 293 8.
32. Ikeguchi M, Nakamura S, Kaibara N. Quantitative analysis of expression levels of bax, bcl-2, and survivin in cancer cells during cisplatin treatment. Oncol Rep. 2002 9 : 1121 6.
33. Berney CR, Downing SR, Yang JL, Russell PJ, Crowe PJ. Evidence for post-transcriptional down-regulation of the apoptosis-related gene bcl-2 in human colorectal cancer. J Pathol. 2000 191 : 15 20.
34. Donnini M, Lapucci A, Papucci L, Witort E, Tempestini A, Brewer G, Bevilacqua A, Nicolin A, Capaccioli S, Schiavone N. Apoptosis is associated with modifications of bcl-2 mRNA AU-binding proteins. Biochem Biophys Res Commun. 2001 287 : 1063 9.
35. Bandyopadhyay S, Sengupta TK, Fernandes DJ, Spicer EK. Taxol- and okadaic acid-induced destabilization of bcl-2 mRNA is associated with decreased binding of proteins to a bcl-2 instability element. Biochem Pharmacol. 2003 66 : 1151 62.
36. Fiorentino M, D'Errico A, Barozzi C, Grigioni WF. Discrepancies between detection of Bcl-2 by in situ hybridization and immunocytochemistry in human prostate cancer tissues. Int J Cancer. 1998 79 : 614 8.
37. Rajasekhar VK, Holland EC. Postgenomic global analysis of translational control induced by oncogenic signaling. Oncogene. 2004 23 : 3248 64.
38. Kleijn M, Scheper GC, Voorma HO, Thomas AA. Regulation of translation initiation factors by signal transduction. Eur J Biochem. 1998 253 : 531 44.